Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer | Scientific Reports
A strategy to overcome EGFR p.T790M cis p.L792F induced resistance to osimertinib - eBioMedicine
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment | British Journal of Cancer
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications - The Lancet Oncology
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations - ScienceDirect
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M | BMC Cancer | Full Text
Cancers | Free Full-Text | Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR - Wu - 2023 - International Journal of Cancer - Wiley Online Library
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
Cancers | Free Full-Text | Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
COSMIC: expanding curation to highlight drug-resistant... | Posters | F1000Research
Figure 1 from Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer | Semantic Scholar
Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR | Biochemistry
Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations - ScienceDirect
IJMS | Free Full-Text | Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy - Kobayashi - 2016 - Cancer Science - Wiley Online Library
4 Inconsistent forward annotation in TCGA and COSMIC. (A)... | Download Scientific Diagram
The alteration of EGFR T790M between 19del and L858R in pre-TKI-treated... | Download Scientific Diagram
Comparison of frequencies of each EGFR mutation between our survey and... | Download Table
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients | Nature Communications
Cancers | Free Full-Text | Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Profiling of circulating tumor DNA in plasma of non‐small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and
EGFR T790M Reference Standard, mutation T790M | Genecopoeia
Epidermal growth factor receptor mutations in lung adenocarcinoma - Laboratory Investigation
